The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Results of a Phase I study of BGB-16673, a BTK degrader, for R/R indolent NHL
Chan Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, outlines the findings of a Phase I study (NCT05006716) of BGB-16673, a BTK degrader, in patients with indolent non-Hodgkin lymphoma (NHL) with a median of 2.5 prior lines of therapy. The agent, which belongs to the proteolysis targeting chimera (PROTAC) drug class, demonstrated clinical activity with an expected safety profile of a BTK-targeting drug. Dr Cheah highlights that the agent holds promise, as it shows activity in patients with previous exposures to both covalent and noncovalent BTK inhibitors (BTKi). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
